SPN-820/821
Treatment-Resistant Depression
Phase 3Active
Key Facts
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a publicly traded CNS-focused biopharmaceutical company with a mission to improve patient lives through innovative neurology and psychiatry treatments. The company has successfully built a commercial foundation with eight marketed products and is advancing a pipeline featuring late-stage candidates for treatment-resistant depression and severe epilepsy. Its strategy combines internal R&D powered by proprietary drug delivery platforms with strategic acquisitions, such as Sage Therapeutics, to solidify its position as a comprehensive CNS therapeutics leader.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| DB104 (Liafensine) | Denovo Biopharma | Phase 2b |
| VNS Therapy for TRD | LivaNova | PMA Supplement |
| Precision Radiomodulation Research | ZAP Surgical | Feasibility Study |
| NOE-101 (basimglurant) | Noema Pharma | Phase 2b |
| PCN-101 (R-ketamine) | Perception Neuroscience | Phase 2a |
| mGlu2 NAM Program for TRD | Camino Pharma | Pre-clinical |
| TAK-653 | Thermo Fisher Scientific | Phase 2 |
| BPL-003 | atai Life Sciences | Phase 2 |
| VLS-01 | atai Life Sciences | Phase 2 |